Belgium and Brazil join forces to advance RNA-based therapies

During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells.

Building upon the successful implementation of Quantoom Biosciences’ Ntensify mRNA production system earlier this year at Bio-Manguinhos/Fiocruz, the MoU establishes a framework for further collaboration between the parties. Key areas outlined include:

· Collaboration between Bio-Manguinhos/Fiocruz and Quantoom Biosciences on the development of second-generation saRNA (self-amplifying RNA) technologies for vaccines in Latin America and beyond.